ESR1 and breast carcinoma: In line with previous reports (Encarnación et al., 1993; Johnston et al., 1995), the ESR1 GEX decreased through tumor progression in patients with luminal PT that had undergone adjuvant endocrine treatment for their primary breast cancer (Supplementary Figures S2, n = 65).